Sponsors (9)
The bill channels significant multi-year federal funding and new program requirements toward expanding overdose prevention, maternal and recovery services, workforce supports, and tribal interventions—strengthening public-health capacity and oversight—but it raises costs for taxpayers, increases administrative and regulatory burdens, and creates risks of privacy concerns and unintended access barriers if implementation, governance, and equity protections are not carefully managed.
State, Tribal, and local health agencies will receive multi-year funding to expand overdose prevention and surveillance programs (authorized ~$505.6M/year FY2026–2030), enabling broader detection and response to overdose threats.
Pregnant and postpartum people (and their infants) will gain expanded maternal and residential substance-use treatment supports through prenatal/postnatal funding and a $38.93M/year residential treatment authorization, improving access to care for this high-need group.
Federal and local programs will have stronger reporting, evaluation, and oversight (HHS reports, GAO study, mandated program evaluations and reviews), increasing transparency and accountability for funded substance-use and mental-health initiatives.
Taxpayers and the federal budget will face substantially higher spending commitments from multiple multi-year authorizations (overdose prevention, residential treatment, loan repayment, grants), which could increase deficits or require offsets.
State/local agencies, nonprofits, and providers will face increased administrative and compliance burdens (evaluation plans, reporting, cybersecurity reporting, sustainability assurances, REMS monitoring), raising costs and staffing needs for implementation.
Regulatory reviews and new safety requirements (rescheduling review for buprenorphine/naloxone; REMS with post‑administration monitoring) could unintentionally limit patient access if they result in stricter controls or delays in implementation.
Based on analysis of 8 sections of legislative text.
Extends and increases authorizations for substance-use prevention, treatment, peer recovery, and overdose surveillance grants through FY2026–2030; broadens overdose-prevention scope and changes some controlled-substance delivery rules.
Introduced June 18, 2025 by Bill Cassidy · Last progress June 18, 2025
Updates and extends federal programs that prevent and treat substance use and overdoses through FY2026–2030, increases authorized funding for several grant programs, broadens the types of substances and surveillance activities covered by overdose-prevention grants, and creates new reporting and evaluation requirements. It also adjusts rules under the Controlled Substances Act to limit pharmacy-to-practitioner deliveries of certain maintenance/detox drugs to injections/implants or drugs subject to strict FDA safety programs, and makes a technical, retroactive education-related edit.